Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, announced that 12 new partner programs entered clinical development in 2023. These programs include collaborations with Biotheus, Cullinan Oncology, IgM Biosciences, Inc., Invivyd, NextPoint, Sensei Biotherapeutics, Takeda, and Therini Bio, bringing the total number of Adimab partner programs that have entered the clinic to 74.
The most advanced program from Adimab’s platform is Tyvyt® (sintilimab), currently marketed in China by Innovent. In 2023, two additional products were approved and another BLA was filed, with three programs currently in pivotal trials.
Philip T. Chase, Chief Executive Officer of Adimab, expressed excitement over the initiation of 12 new clinical programs in 2023, especially considering the challenging financial market conditions that have affected many biotech companies. He highlighted the company's pride in generating a wide range of clinical molecules, including multispecifics and CAR-T programs.
Guy Van Meter, Chief Business Officer of Adimab, noted the rewarding experience of seeing additional marketed programs in 2023 and anticipated several more in 2024. He emphasized that Adimab's success is fully aligned with the success of its partners, as the company does not have a potentially competitive internal pipeline or venture studio.
Adimab partners have exercised more than 95 commercial licenses to advance programs toward clinical development. In 2023, partners exercising commercial options included Anokion, BYOMass, Compugen, IgM Biosciences, Inc., and Kelonia, among others.
Adimab's technologies include antibody discovery in IgG and single domain (HCab) formats through proprietary yeast-based technology, engineering capabilities refined over thousands of lead antibody optimization efforts, extensive multispecific capabilities, and proprietary solutions for Fc (HC:HC) and Fab (HC:LC) heterodimerization. The company has also developed proprietary workflows for complex targets, such as GPCRs and ion channels, allowing for discovery against membrane-obligate proteins in their native state.
Since 2009, Adimab has partnered with over 115 pharmaceutical and biotechnology companies, generating more than 525 therapeutic programs and over 70 clinical programs. The Adimab technology has been transferred and implemented at major pharmaceutical companies, including Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda.
